Slides from Driving Advances in Liver Health—NASH: Hit the Ground Running

Expert insights on emerging NAFLD/NASH treatments from Dr. Stephen Harrison and Clinical Care Options (CCO)

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Video from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 9, 2021 Expired: September 8, 2022

Prevalence and Pathogenesis

Risk Factors and Screening

Current Management

Emerging Agents

Downloadable slides from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: September 9, 2021

From Clinical Care Options (CCO) and Global Liver Institute: Easy-to-read reminders on why and how to look for NAFLD and NASH in your patients: FIB-4, VCTE, MRE, and more